Background: Anaesthesia of a patient with myasthenia gravis requires special preoperative management and proper choice of intraoperative agents. The disease should be treated until surgery and some anaesthetics (e.g. barbiturates, benzodiazepines) eliminated. Moreover, the choice of opioids providing suitable intraoperative analgesia is relevant.
Case Report: We present a case of a 68-year-old male patient, ASA II, with the 10-year history of myasthenia gravis scheduled for glaucoma surgery. Premedication was not administered. Anaesthesia was induced with fentanyl and propofol. After endotracheal intubation, anaesthesia was maintained with the mixture of N(2)O and O(2) (1:2), the infusion of propofol and remifentanil. Remifentanil was administered in iv continuous infusion in the dose of 0.04 microg kg(-1) min(-1) followed by 0.08 microg kg(-1) min(-1). Muscle relaxants were not used. Anaesthesia was uneventful, except for transient bradycardia (HR-43 min(-1)). The patient recovered 5 min after surgery and was extubated after the further 3 min. No postoperative muscle weakness and respiratory failure were observed.
Discussion: Surgical treatment of a patient with myasthenia may intensify adverse manifestations of the disease. To provide safe anaesthesia, muscle relaxants should be avoided and remifentanil used. The onset of action of this selective opioid receptor agonist is rapid and its residual activity short-term. Remifentanil ought to be the drug of choice in patients with myasthenia gravis.
Download full-text PDF |
Source |
---|
Ann Clin Transl Neurol
December 2024
Transplant and Cell Therapy Program, Division of Hematology, Department of Medicine, The Ottawa Hospital, Ottawa, Ontario, Canada.
Objectives: Patients with refractory myasthenia gravis (MG) have few treatment options. Autologous hematopoietic stem cell transplantation (HSCT) has been used to treat immune diseases; however, its use in the treatment of MG is not broadly considered. Our objective is to report on the efficacy and safety of HSCT in refractory MG.
View Article and Find Full Text PDFTher Adv Neurol Disord
December 2024
Huashan Rare Disease Center and Department of Neurology, Huashan Hospital, Shanghai Medical College, National Center for Neurological Disorders, Fudan University, No.12 Urumqi Middle Road, Jing 'an District, Shanghai 200040, China.
Background: Thymoma-associated myasthenia gravis (TAMG) is a subtype of myasthenia gravis (MG) that is associated with more severe symptoms and a relatively poor prognosis. Eculizumab, an inhibitor to target human C5 component of the complement cascade, is considered a treatment option for refractory generalized MG (gMG).
Objectives: To explore the safety and efficacy of eculizumab in patients with TAMG.
Ther Adv Neurol Disord
December 2024
Department of Neurology, Faculty of Medicine, University of Augsburg, Stenglinstrasse 2, Augsburg 86156, Germany.
In acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG), neonatal Fc-receptor (FcRn) inhibition has broadened the therapeutic spectrum. Myasthenic crisis (MC), heralded by an impending myasthenic crisis (iMC), is a critical condition requiring treatments with rapid onset and sustained efficacy. Currently treatments used for iMC, including intravenous immunoglobulins and plasma exchange/immunoadsorption, have limitations, such as delayed onset of action and potential side effects.
View Article and Find Full Text PDFCureus
November 2024
Neurology, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, USA.
Myasthenia gravis (MG) is one of the most common neuromuscular disorders. It is an antibody-mediated autoimmune disease affecting the neuromuscular junction, presenting with fluctuating muscle weakness that commonly affects the ocular, bulbar, proximal, and respiratory muscles. Treating MG in the older population with preexisting comorbidities can be challenging.
View Article and Find Full Text PDFNeurol Sci
December 2024
Eastern Health Clinical School, Monash University, Box Hill Hospital, Melbourne, VIC, 3128, Australia.
Introduction/aims: Previous studies have demonstrated high morbidity and mortality in patients with myasthenia gravis (MG) who acquired COVID-19. We aimed to identify the impact of the pandemic on MG disease control, treatment and quality of life.
Methods: A prospective observational cohort study was conducted to identify the impact of the COVID-19 pandemic on Australian patients with MG.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!